Davide Giuseppe Ribaldone
Overview
Explore the profile of Davide Giuseppe Ribaldone including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
160
Citations
1252
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tovo P, Ribaldone D, Caviglia G, Calvi C, Montanari P, Tizzani M, et al.
Cells
. 2025 Feb;
14(3).
PMID: 39936987
Irritable bowel syndrome (IBS) is a common disease, whose etiopathogenesis is poorly understood. Human endogenous retroviruses (HERVs) originate from ancient infections of germinal cells and represent 8% of our DNA....
2.
Lopetuso L, Deleu S, Puca P, Abreu M, Armuzzi A, Barbara G, et al.
Inflamm Bowel Dis
. 2025 Feb;
PMID: 39932857
Background: Fecal microbiota transplantation (FMT) is emerging as a potential treatment modality for individuals living with inflammatory bowel disease (IBD). Despite its promise, the effectiveness of FMT for treating IBD,...
3.
Zaccardi B, Armandi A, Caviglia G, Broglio F, Vernero M, Bombonato M, et al.
J Clin Med
. 2025 Jan;
14(1.
PMID: 39797226
The characterization of patients with inflammatory bowel disease (IBD) and type 2 diabetes mellitus (T2DM) as a new group has not been well detailed. This study aimed to evaluate the...
4.
Cusato J, Ribaldone D, D Avolio A, Infusino V, Antonucci M, Caviglia G, et al.
J Clin Med
. 2024 Dec;
13(23).
PMID: 39685734
: Vitamin D (VD) has immunoregulatory properties, generating interest in its potential to influence therapeutic outcomes in inflammatory bowel disease (IBD), other than affecting the expression of genes encoding enzymes...
5.
Bezzio C, Brinch D, Ribaldone D, Cappello M, Ruzzon N, Vernero M, et al.
Nutrients
. 2024 Dec;
16(23).
PMID: 39683376
Introduction: The prevalences of malnutrition and sarcopenia in patients with IBD are not precisely known, and nutritional assessment is not standardized. We assessed the prevalence and risk factors of these...
6.
Tovo P, Ribaldone D, Galliano I, Caviglia G, Dini M, Veglio V, et al.
Viruses
. 2024 Oct;
16(10).
PMID: 39459904
Inflammatory bowel disease (IBD) includes patients affected by Crohn's disease or ulcerative colitis. IBD is thought to be a chronic immune-mediated disease, but its origin remains elusive, and this limits...
7.
Goren I, Fallek Boldes O, Boldes T, Knyazev O, Kagramanova A, Limdi J, et al.
J Crohns Colitis
. 2024 Oct;
PMID: 39435855
Objectives: Elderly hospitalized patients with inflammatory bowel disease (IBD) flare and concurrent Clostridioides difficile infection (CDI) are considered at high risk of IBD-related complications. We aimed to evaluate the short,...
8.
Ammirata G, Arigoni M, Licastro D, Caviglia G, Disabato M, Zubair G, et al.
Antioxidants (Basel)
. 2024 Sep;
13(9).
PMID: 39334706
The relationship between serum 25-hydroxyvitamin D (25(OH)D) levels, genomic response to vitamin D (Vit.D), and positivity to SARS-CoV-2 remains understudied. In this pilot study, during the follow-up of patients with...
9.
Calabrese E, Onali S, Variola A, Ribaldone D, Savarino E, Viola A, et al.
Dig Liver Dis
. 2024 Sep;
57(1):241-250.
PMID: 39299813
Background And Aim: Suboptimal disease control (SDC) and its contributing factors in IBD according to STRIDE-II criteria is unclear. IBD-PODCAST was a non-interventional, international, multicenter real-world study to assess this....
10.
Cusato J, Ribaldone D, Falzone M, Manca A, Antonucci M, Palermiti A, et al.
Biomedicines
. 2024 Apr;
12(4).
PMID: 38672179
Over the years, vedolizumab (VDZ) has emerged as a more effective target therapy for inflammatory bowel disease. The aim of this work was to analyze a cohort of inflammatory bowel...